Next Article in Journal
Identifizierung und Unterscheidung von H2-Antihistaminika und Thioharnstoffderivaten durch Farbreaktionen mit Kupfer(II)-Salzen in stark saurer Lösung
[ Identification and differentiation of H2-antihistamines and thiourea derivatives by colour reaction with Copper(II)-salts in acidic solutions ]
Previous Article in Journal
Investigation of the Direct Effects of the Alcoholic Extract of Elaeagnus angustifolia L. (Elaeagnaceae) on Dispersed Intestinal Smooth Muscle Cells of Guinea Pig
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories

Basmah N. Al-Dossary
Omaimah M.N. Al-Gohary
Manal M. El-Khawaas
Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O.Box 22452, Riyadh 11459, Saudi Arabia
Author to whom correspondence should be addressed.
Sci. Pharm. 2006, 74(1), 31-51;
Submission received: 10 May 2005 / Accepted: 2 February 2006 / Published: 1 March 2006


Mebeverine hydrochloride suppositories were prepared using Witepsol H15 suppository base. The effect of different concentrations of various enhancers (surfactants, amino acids and osmotic modifiers) on the drug release form the prepared suppositories was studied. The results showed that mebeverine hydrochloride suppositories containing Brij 35 (2%) and urea (10%) were superior to the other formulations containing the tested enhancers. These formulae showed the highest release rates (K = 0.083 ± 0.004 min-1 and 0.111 ± 0.005 min-1 , respectively) that followed first-order kinetics with t50% of 8.35 ± 0.45 min and 6.24 ± 0.33 min, respectively. Therefore, these two formulae with the control suppositories were subjected to in vivo study in albino rabbits compared to the commercial Duspatalin® tablets and intravenous injection. Higher Cmax (1770.26 ± 165.46 within shorter Tmax (0.75 ± 0.20 h) was observed after rectal administration of the control suppositories compared to that of commercially available film-coated tablets (Duspatalin® – 135 mg). A significant difference (p≤0.05) between the absolute bioavailability of Duspatalin® tablets (27.09 ± 3.80%) and control suppositories (46.66 ± 1.72%) was detected. Statistically (p≤0.05), the mean residence time (MRT) after oral administration of Duspatalin® tablets (3.16 ± 0.30 h) was significantly longer than that after the rectal administration of control suppositories (2.73 ± 0.30 h). suppositories containing 2% Brij 35 showed higher plasma levels of the drug (2766.11± 339.50 with an absolute bioavailability of 70.50 ± 10.51% compared to 27.09 ± 3.80% for Duspatalin® tablets.
Keywords: Mebeverine hydrochloride; suppositories; in vitro and in vivo availability; enhancers; HPLC Mebeverine hydrochloride; suppositories; in vitro and in vivo availability; enhancers; HPLC

Share and Cite

MDPI and ACS Style

Al-Dossary, B.N.; Al-Gohary, O.M.N.; El-Khawaas, M.M. In-vitro and in-vivo availability of mebeverine hydrochloride suppositories. Sci. Pharm. 2006, 74, 31-51.

AMA Style

Al-Dossary BN, Al-Gohary OMN, El-Khawaas MM. In-vitro and in-vivo availability of mebeverine hydrochloride suppositories. Scientia Pharmaceutica. 2006; 74(1):31-51.

Chicago/Turabian Style

Al-Dossary, Basmah N., Omaimah M.N. Al-Gohary, and Manal M. El-Khawaas. 2006. "In-vitro and in-vivo availability of mebeverine hydrochloride suppositories" Scientia Pharmaceutica 74, no. 1: 31-51.

Article Metrics

Back to TopTop